BiotechTube

Navepegritide + Placebo for navepegritide

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Achondroplasia

Conditions

Achondroplasia

Trial Timeline

Dec 10, 2024 → Jan 1, 2027

NCT ID
NCT06732895

About Navepegritide + Placebo for navepegritide

Navepegritide + Placebo for navepegritide is a phase 2 stage product being developed by Ascendis Pharma for Achondroplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06732895. Target conditions include Achondroplasia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT06732895Phase 2Recruiting
NCT06079398Phase 2Recruiting

Competing Products

20 competing products in Achondroplasia

See all competitors
ProductCompanyStageHype Score
KK8398Kyowa KirinPhase 3
77
ReciferceptPfizerPhase 2
51
ReciferceptPfizerPhase 2
51
TransCon CNPAscendis PharmaPhase 2/3
62
TransCon CNP + Placebo for TransCon CNPAscendis PharmaPhase 2/3
62
TransCon CNP + Placebo for TransCon CNPAscendis PharmaPhase 2
49
Navepegritide + Placebo for NavepegritideAscendis PharmaPhase 2
49
TransCon CNP + Placebo for TransCon CNPAscendis PharmaPhase 2
49
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injectionsAscendis PharmaPhase 2
49
BMN 111 + Normal SalineBioMarin PharmaceuticalPhase 1
30
BMN 111BioMarin PharmaceuticalPhase 2
49
BMN 111 + PlaceboBioMarin PharmaceuticalPhase 2
49
BMN 111 administration via vial and syringeBioMarin PharmaceuticalPhase 1
30
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.BioMarin PharmaceuticalPhase 2
49
BMN 111BioMarin PharmaceuticalPhase 2
49
BMN 111 + PlaceboBioMarin PharmaceuticalPhase 3
74
BMN 333 + Vosoritide Injection [Voxzogo]BioMarin PharmaceuticalPhase 2/3
62
vosoritideBioMarin PharmaceuticalPhase 2
49
BMN 111BioMarin PharmaceuticalPhase 3
74
TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.50 mg/kgTyra BiosciencesPhase 2
47

Other Products from Ascendis Pharma

Lonapegsomatropin + SomatropinPhase 3
74
Once weekly subcutaneous injection of TransCon hGH + Once daily subcutaneous injection of GenotropinPhase 3
74
LonapegsomatropinPhase 3
74
TransCon hGHPhase 3
74
TransCon hGHPhase 3
74